Open AccessNucleic Acid Immunotherapeutics for Cancer
Author(s) -
Tingting Shen,
Yu Zhang,
Shurong Zhou,
Shuibin Lin,
Xiaobing Zhang,
Guizhi Zhu
Publication year - 2020
Publication title -
acs applied bio materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.764
H-Index - 17
ISSN - 2576-6422
DOI - 10.1021/acsabm.0c00101
Subject(s) - nucleic acid , immunotherapy , oncolytic virus , biology , cancer immunotherapy , cancer , immune system , computational biology , cancer research , immunology , biochemistry , genetics
The past decade has witnessed the blossom of two fields: nucleic acid therapeutics and cancer immunotherapy. Unlike traditional small molecule medicines or protein biologics, nucleic acid therapeutics have characteristic features such as storing genetic information, immunomodulation, and easy conformational recovery. Immunotherapy uses the patients' own immune system to treat cancer. A variety of strategies have been developed for cancer immunotherapy including immune checkpoint blockade, adoptive cell transfer therapy, therapeutic vaccines, and oncolytic virotherapy. Interestingly, nucleic acid therapeutics have emerged as a pivotal class of regimen for cancer immunotherapy. Examples of such nucleic acid immunotherapeutics include immunostimulatory DNA/RNA, mRNA/plasmids that can be translated into immunotherapeutic proteins/peptides, and genome-editing nucleic acids. Like many other therapeutic nucleic acids, nucleic acid immunotherapeutics often require chemical modifications to protect them from enzymatic degradation and need drug delivery systems for optimal delivery to target tissues and cells and subcellular locations. In this review, we attempted to summarize recent advancement in the interfacial field of nucleic acid immunotherapeutics for cancer treatment.